Mylan Receives Tentative Approval for Pioglitazone Hydrochloride TabletsPITTSBURGH, Nov. 9 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Pioglitazone Hydrochloride Tablets, 15 mg, 30 mg, and 45 mg.

Pioglitazone Hydrochloride Tablets are the generic version of Takeda Pharmaceuticals' Actos^® Tablets.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

SOURCE Mylan Laboratories Inc.
11/09/2004
CONTACT: Media, Heather Bresch, +1-724-514-1800, or Investors, Kris King, +1-724-514-1800, both of Mylan Laboratories Inc.
Web site: http://www.mylan.com